Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EC Approves Merck’s Keytruda as Adjuvant Therapy for Resected Stage III Melanoma

By Merck & Co., Inc. | December 18, 2018

(Credit: Merck & Co., Inc.)

The European Commission has approved Merck & Co.’s Keytruda anti-PD-1 therapy for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection.

This approval is based on data from the pivotal Phase 3 EORTC1325/KEYNOTE-054 trial, conducted in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).

An updated recurrence-free survival data analysis, conducted at the request of the European Medicines Agency, demonstrated that Keytruda significantly prolonged recurrence-free survival, reducing the risk of disease recurrence or death by 44 percent compared to placebo in the overall population of patients with resected, high-risk stage III melanoma (HR=0.56; 98% CI, 0.44-0.72; p<0.0001).

“Merck’s long-term commitment to melanoma patients includes a particular focus on bringing new treatment options to these patients earlier in the treatment paradigm,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “This approval, which is the first for Keytruda in the adjuvant setting in the European Union, builds upon the foundation established by Keytruda in the advanced and metastatic melanoma settings.”

The approval allows marketing of Keytruda in this new indication in all 28 EU member states plus Iceland, Lichtenstein, and Norway, at the approved dose of 200 mg every three weeks until disease recurrence, unacceptable toxicity, or for a duration of up to one year.

Keytruda is also approved in Europe as a monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.

“Melanoma patients, particularly those with stage III disease, often have a high risk of recurrence, and the collaborative study from EORTC and Merck demonstrated a significant reduction in the risk of cancer returning after surgery,” said Dr. Alexander Eggermont, study chair, director general at the Gustave Roussy Cancer Institute, Professor of Oncology, University of Paris-Saclay. “This approval in the adjuvant setting marks another important milestone in the treatment of melanoma.”

Merck is known as MSD outside the United States and Canada.

(Source: Merck & Co., Inc.)


Filed Under: Oncology

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer 
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia
oncopeptides
Oncopeptides’ Pepaxti wins positive opinion from CHMP for multiple myeloma patients
DNA sequencer
Localizing next-generation sequencing testing for cancer patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50